ProCE Banner Activity

Treatment Considerations for Patients With Essential Thrombocythemia: A Conversation Between Experts

Clinical Thought

Two experts discuss their approach to managing patients with essential thrombocythemia, including the role of CALR mutations, cytoreductive therapy, and JAK inhibition.

Released: February 23, 2023

Expiration: February 22, 2024

Share

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

GSK

Incyte Corporation

PharmaEssentia Corp

Disclosure

Prithviraj Bose, MD: consultant/advisor/speaker: AbbVie, Blueprint, Bristol-Myers Squibb, Cogent, CTI BioPharma, Incyte, Karyopharm, MorphoSys, Novartis, Pharma Essentia, Sierra Oncology (GlaxoSmithKline); researcher: Blueprint, Bristol-Myers Squibb, Cogent, CTI BioPharma, Disc Medicine, Incyte, Ionis, Kartos, MorphoSys, Telios.

Andrew Kuykendall, MD: consultant/advisor/speaker: AbbVie, Blueprint, Bristol-Myers Squibb, CTI BioPharma, Imago, Incyte, MorphoSys, SDP Oncology, Sierra/GlaxoSmithKline.